Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 7 Thyroid Neoplasms 3 Neoplasm Metastasis 2 Triple Negative Breast Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Myelomonocytic, Chronic 1 Hodgkin Disease 1 Endocrine Gland Neoplasms 1 Carcinoma, Intraductal, Noninfiltrating 1 Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 29 Everolimus 19 Temozolomide 11 gallium Ga 68 dotatate 10 Nivolumab 10 Magnetic Resonance Spectroscopy 10 Capecitabine 9 pembrolizumab 8 lanreotide 8 Positron Emission Tomography Computed Tomography 8 cabozantinib 7 3-Iodobenzylguanidine 7 177Lu-octreotide, DOTA(0)-Tyr(3)- 7 Somatostatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 lenvatinib 5 Octreotide 5 Lutetium-177 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Carboplatin 5 avelumab 4 Positron-Emission Tomography 4 Ipilimumab 4 Bevacizumab 4 surufatinib 3 pasireotide 3 fluorodopa F 18 3 copper dotatate CU-64 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroendocrine Tumors × Biopsy, Large-Core Needle × Clear all

NCT03130205 2017-08-25

PROGRESS

Uppsala University

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡